The activation of the PI3K/AKT signaling pathway is a key that plays a crucial role in leading to higher invasiveness and migration ability of ovarian cancer cells [11, 12], and consistent with mRNA sequencing results, the GA treatment significantly reduced the protein levels of p-PI3K and p-AKT, but not total PI3K and AKT, which are shown in Figure 4A. Aims to further clarify whether GA played its anticancer effect dependent on the PI3K/AKT pathway, the PI3K/Akt/CREB activator 1 (compound AE-18) was added and co-incubated with GA on A2780 cells. The gene discussed is AKT1; the disease is ovarian cancer.